Tag:
Merck KGaA
Latest Headlines
Latest Headlines
Latin American cancer vax races Big Pharma rivals
The lung cancer vaccine race has brought together an unusual mix of players. Merck KGaA was in a good position, but its vaccine disappointed in Phase III, while GlaxoSmithKline could report data on its candidate this year. Then there is the Cuba-Argentina joint venture.
Luminex re-ups assay deal with Merck KGaA
Luminex has inked a long-term agreement with Merck KGaA's life sciences business, tasking the German company with providing assays for Luminex's research technology.
Quintiles signs on to help Merck KGaA right the R&D ship
Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.
Mylan Napa plant to close by year-end
Mylan has had an on-again, off-again relationship with the former Dey plant in Napa County, CA. The plan to close it is back on and by year's end the lights will be off.
Novartis vaccines unit's future hangs on Bexsero approval
Novartis' ($NVS) vaccine business is hanging in the balance, relying on the potential approval of a shot to protect against a meningitis-causing bacteria to keep the unit afloat.
CMOs move toward disposable manufacturing tech
The CMO units of Merck KGaA and Boehringer Ingelheim are investing in single-use, disposable technolgies in their manufacturing processes, saying the move will help their clients get drugs on the market faster than traditional methods.
UPDATED: Contractors pushing disposable manufacturing processes
With drug companies looking for ways to get to market faster and start realizing revenue streams sooner, two European contract manufacturers are touting single-use, disposable technology that they claim will help customers do just that.
2 Merck KGaA production facilities whacked in cuts
Putting some specifics to plans it announced in February to cut its workforce about 10%, Merck KGaA says two production facilities will be closed as part of the downsizing.
MDxHealth signs deal with Merck KGaA for cancer Dx
Molecular diagnostics firm MDxHealth has inked a development and commercialization deal with Merck KGaA, looking to market a companion diagnostic test for one of the drugmaker's cancer treatments.
No new cuts to manufacturing in final Merck Serono reduction
Well it's done. Merck KGaA put the finishing touches on a restructuring plan for Merck Serono that closes the Geneva half of its two-headquarters setup, but which leaves its manufacturing operations in Switzerland mostly intact.
